Maurizio Averna

23.3k total citations · 3 hit papers
288 papers, 9.6k citations indexed

About

Maurizio Averna is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Maurizio Averna has authored 288 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 161 papers in Surgery, 100 papers in Endocrinology, Diabetes and Metabolism and 95 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Maurizio Averna's work include Lipoproteins and Cardiovascular Health (127 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (76 papers) and Lipid metabolism and disorders (58 papers). Maurizio Averna is often cited by papers focused on Lipoproteins and Cardiovascular Health (127 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (76 papers) and Lipid metabolism and disorders (58 papers). Maurizio Averna collaborates with scholars based in Italy, United States and Spain. Maurizio Averna's co-authors include Davide Noto, A Notarbartoló, Angelo B. Cefalù, Giovanni Davı̀, Carlo M. Barbagallo, Michel Farnier, Erik S.G. Stroes, Gregorio Caimi, Carlo Patrono and Patrizia Tarugi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Maurizio Averna

278 papers receiving 9.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015 1.7k citations Maurizio Averna et al. profile →
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

2012 524 citations Marina Cuchel, Emma A. Meagher et al. profile →
Thromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus

1990 485 citations Giovanni Davı̀, Maurizio Averna et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maurizio Averna Italy	45	5.2k	2.9k	2.8k	1.2k	1.2k	288	9.6k
L. Masana Spain	49	4.6k 0.9×	3.0k 1.1×	2.4k 0.8×	1.3k 1.0×	1.5k 1.2×	376	10.0k
Heinz Drexel Austria	40	4.2k 0.8×	2.6k 0.9×	2.5k 0.9×	1.2k 1.0×	927 0.7×	298	8.7k
Sergio Fazio United States	44	4.6k 0.9×	2.3k 0.8×	1.9k 0.7×	890 0.7×	1.2k 1.0×	143	8.0k
Gérald Luc France	46	3.1k 0.6×	2.6k 0.9×	3.0k 1.1×	1.1k 0.9×	1.1k 0.8×	88	9.1k
Eleanor Danielson United States	10	5.6k 1.1×	2.2k 0.8×	2.8k 1.0×	1.9k 1.5×	992 0.8×	16	10.0k
Jiří Fröhlich Canada	51	4.8k 0.9×	3.8k 1.3×	2.3k 0.8×	1.3k 1.1×	1.2k 1.0×	166	10.2k
Marianne Benn Denmark	43	4.1k 0.8×	3.3k 1.1×	2.6k 0.9×	1.2k 1.0×	1.3k 1.1×	121	8.6k
John R. Guyton United States	53	6.2k 1.2×	3.3k 1.2×	2.5k 0.9×	1.7k 1.3×	1.8k 1.4×	166	12.0k
Fernando Civeira Spain	43	4.9k 0.9×	2.4k 0.8×	1.9k 0.7×	543 0.4×	1.4k 1.1×	286	8.0k
G. Kees Hovingh Netherlands	52	7.4k 1.4×	4.2k 1.5×	2.7k 1.0×	951 0.8×	1.9k 1.6×	204	11.8k

Countries citing papers authored by Maurizio Averna

Since Specialization

Citations

This map shows the geographic impact of Maurizio Averna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maurizio Averna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maurizio Averna more than expected).

Fields of papers citing papers by Maurizio Averna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maurizio Averna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maurizio Averna. The network helps show where Maurizio Averna may publish in the future.

Co-authorship network of co-authors of Maurizio Averna

This figure shows the co-authorship network connecting the top 25 collaborators of Maurizio Averna. A scholar is included among the top collaborators of Maurizio Averna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maurizio Averna. Maurizio Averna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kessler, Asia Sikora, T. Michelle Brown, Emily Bratlee‐Whitaker, et al.. (2025). Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants. Journal of clinical lipidology. 19(5). 1243–1255. 1 indexed citations

Giammanco, Antonina, Augusto Vaglio, Francesco Pegoraro, et al.. (2024). Erdheim-Chester disease as complex clinical presentation and diagnosis: A case report and concise review of literature. Medicine. 103(17). e37870–e37870. 1 indexed citations

Averna, Maurizio & Angelo B. Cefalù. (2024). LP(a): The new marker of high cardiovascular risk. Nutrition Metabolism and Cardiovascular Diseases. 35(3). 103845–103845. 1 indexed citations

Averna, Maurizio. (2024). Novel approaches to lipid lowering. 3(2). 51–53. 1 indexed citations

Santos, Raúl D., Albert Wiegman, Sonia Caprio, et al.. (2024). Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia. JAMA Pediatrics. 178(3). 283–283. 11 indexed citations

Tarugi, Patrizia, Stefano Bertolini, S. Calandra, et al.. (2024). Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA). Nutrition Metabolism and Cardiovascular Diseases. 34(8). 1819–1836. 4 indexed citations

Giammanco, Antonina, Davide Noto, Emilio Nardi, et al.. (2024). Do genetically determined very high and very low LDL levels contribute to Lp(a) plasma concentration?. Nutrition Metabolism and Cardiovascular Diseases. 35(2). 103723–103723.

Chiesa, Giulia, Maria Grazia Zenti, Andrea Baragetti, et al.. (2023). Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA). Nutrition Metabolism and Cardiovascular Diseases. 33(10). 1866–1877. 4 indexed citations

Barbagallo, Carlo M., Angelo B. Cefalù, Antonina Giammanco, et al.. (2021). Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life. 11(4). 315–315. 23 indexed citations

10.

Cesaro, Arturo, Fabio Fimiani, Felice Gragnano, et al.. (2021). New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. Heart Failure Clinics. 18(1). 177–188. 16 indexed citations

11.

Gulizia, Michele Massimo, Aldo P. Maggioni, Maurizio Giuseppe Abrignani, et al.. (2020). Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis. 308. 32–38. 8 indexed citations

12.

Casula, Manuela, Marta Gazzotti, Marcello Arca, et al.. (2020). Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study. Journal of Internal Medicine. 290(1). 116–128. 25 indexed citations

13.

Mattina, Alessandro, Antonina Giammanco, Philippe Giral, et al.. (2019). Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender. Nutrition Metabolism and Cardiovascular Diseases. 29(10). 1068–1076. 12 indexed citations

14.

Licata, Anna, et al.. (2018). Liver and Statins: A Critical Appraisal of the Evidence. Current Medicinal Chemistry. 25(42). 5835–5846. 18 indexed citations

15.

Cuchel, Marina, Dirk Blom, Maurizio Averna, et al.. (2013). Abstract 16516: Sustained LDL-C Lowering and Stable Hepatic Fat Levels in Patients With Homozygous Familial Hypercholesterolemia Treated With the Microsomal Triglyceride Transfer Protein Inhibitor, Lomitapide: Results of an Ongoing Long-Term Extension Study. Circulation. 11 indexed citations

16.

Cuchel, Marina, Emma A. Meagher, Dirk Blom, et al.. (2012). Abstract 17396: Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia. Circulation. 126. 3 indexed citations

17.

Srivastava, Neelam, Maurizio Averna, & Rai Ajit K. Srivastava. (2008). Dietary Cholesterol and Estrogen Administration Elevate Brain Apolipoprotein E in Mice by Different Mechanisms. Annals of Neurosciences. 15(4). 89–93. 2 indexed citations

18.

Carroccio, Antonio, C. Scalici, Emiliano Maresi, et al.. (2005). Chronic constipation and food intolerance: A model of proctitis causing constipation. Scandinavian Journal of Gastroenterology. 40(1). 33–42. 36 indexed citations

19.

Averna, Maurizio, Carlo M. Barbagallo, Antonina Ganci, et al.. (2001). Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney International. 59(4). 1574–1579. 17 indexed citations

20.

Davı̀, Giovanni, G.B. Rini, Maurizio Averna, et al.. (1982). Enhanced Platelet Release Reaction in Insulin-Dependent and Insulin-Independent Diabetic Patients. Pathophysiology of Haemostasis and Thrombosis. 12(3). 275–281. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact